NASDAQ : KZR
Kezar Life Sciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 7.29 USD (At close: May 8, 2026) · Market cap 53.86M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 53.86M |
| Enterprise Value | -11.02M |
Dates
| Measure | Value |
|---|
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 7.39M |
| Shares Outstanding | 7.39M |
| Shares Change (YoY) | +0.41% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 2.15% |
| Owned by Institutions (%) | 47.41% |
| Float | 5.17M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.82 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 24.46 |
| Quick Ratio | 23.98 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -74.85 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -53.75% |
| Return on Assets (ROA) | -26.77% |
| Return on Invested Capital (ROIC) | -28.16% |
| Return on Capital Employed (ROCE) | -63.45% |
| Weighted Average Cost of Capital (WACC) | 7.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.03M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.41 |
| 52-Week Price Change | +78.68% |
| 50-Day Moving Average | 7.12 |
| 200-Day Moving Average | 5.79 |
| Relative Strength Index (RSI) | 52.55 |
| Average Volume (20 Days) | 127,531 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 151,602 |
| Short Previous Month | 201,330 |
| Short % of Shares Out | 2.05% |
| Short % of Float | 2.93% |
| Short Ratio (days to cover) | 1.31 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -33.76M |
| Operating Income | -41.39M |
| Pretax Income | -45.23M |
| Net Income | -45.23M |
| EBITDA | -40.70M |
| EBIT | -41.39M |
| Earnings Per Share (EPS) | -$6.17 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 66.23M |
| Total Debt | 1.35M |
| Net Cash | 64.88M |
| Net Cash Per Share | $8.78 |
| Equity (Book Value) | 65.24M |
| Book Value Per Share | 8.85 |
| Working Capital | 64.80M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -42.03M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 693,000 |
| Net Borrowing | -9.35M |
| Free Cash Flow | -42.03M |
| FCF Per Share | -$5.69 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.41% |
| Shareholder Yield | -0.41% |
| Earnings Yield | -83.99% |
| FCF Yield | -78.04% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.00 |
| Price Target Difference | -17.70% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |